RESUMEN
Failures in mitophagy, a process by which damaged mitochondria are cleared, results in neurodegeneration, while enhancing mitophagy promotes the survival of dopaminergic neurons. Using an artificial intelligence platform, we employed a natural language processing approach to evaluate the semantic similarity of candidate molecules to a set of well-established mitophagy enhancers. Top candidates were screened in a cell-based mitochondrial clearance assay. Probucol, a lipid-lowering drug, was validated across several orthogonal mitophagy assays. In vivo, probucol improved survival, locomotor function, and dopaminergic neuron loss in zebrafish and fly models of mitochondrial damage. Probucol functioned independently of PINK1/Parkin, but its effects on mitophagy and in vivo depended on ABCA1, which negatively regulated mitophagy following mitochondrial damage. Autophagosome and lysosomal markers were elevated by probucol treatment in addition to increased contact between lipid droplets (LDs) and mitochondria. Conversely, LD expansion, which occurs following mitochondrial damage, was suppressed by probucol and probucol-mediated mitophagy enhancement required LDs. Probucol-mediated LD dynamics changes may prime the cell for a more efficient mitophagic response to mitochondrial damage.
Asunto(s)
Gotas Lipídicas , Probucol , Animales , Probucol/farmacología , Inteligencia Artificial , Mitofagia , Pez CebraRESUMEN
Oxidative stress is pivotal in retinal disease progression, causing dysfunction in various retinal components. An effective antioxidant, such as probucol (PB), is vital to counteract oxidative stress and emerges as a potential candidate for treating retinal degeneration. However, the challenges associated with delivering lipophilic drugs such as PB to the posterior segment of the eye, specifically targeting photoreceptor cells, necessitate innovative solutions. This study uses formulation-based spray dry encapsulation technology to develop polymer-based PB-lithocholic acid (LCA) nanoparticles and assesses their efficacy in the 661W photoreceptor-like cell line. Incorporating LCA enhances nanoparticles' biological efficacy without compromising PB stability. In vitro studies demonstrate that PB-LCA nanoparticles prevent reactive oxygen species (ROS)-induced oxidative stress by improving cellular viability through the nuclear erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. These findings propose PB-LCA nanoparticles as a promising therapeutic strategy for oxidative stress-induced retinopathies.
Asunto(s)
Antioxidantes , Ácido Litocólico , Nanopartículas , Estrés Oxidativo , Polímeros , Probucol , Especies Reactivas de Oxígeno , Probucol/farmacología , Probucol/administración & dosificación , Probucol/química , Estrés Oxidativo/efectos de los fármacos , Nanopartículas/química , Especies Reactivas de Oxígeno/metabolismo , Ácido Litocólico/química , Ácido Litocólico/farmacología , Animales , Polímeros/química , Línea Celular , Antioxidantes/farmacología , Antioxidantes/química , Factor 2 Relacionado con NF-E2/metabolismo , Supervivencia Celular/efectos de los fármacos , Ratones , Hemo-Oxigenasa 1/metabolismo , HumanosRESUMEN
Probucol is a hyperlipidemic drug with antioxidant properties. It has been reported to prevent mitochondrial dysfunction, reduce oxidative stress, and suppress neurotoxicity in neurodegenerative disease models, including Parkinson's disease models. However, the molecular mechanisms underlying the neuroprotective effects of probucol have been not examined yet. Thus, in this study, we investigated whether probucol can alleviate the effects of a mitochondrial complex I inhibitor, rotenone, on a human neuroblastoma cell line (SH-SY5Y). We evaluated the cell viability and cytotoxicity and apoptosis rates of SH-SY5Y cells treated with rotenone and probucol or edaravone, a known free-radical scavenger. Subsequently, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels in the cells were evaluated to determine the effects of probucol on mitochondrial function. We found that rotenone caused cytotoxicity, cell apoptosis, and mitochondrial dysfunction, enhanced ROS generation, and impaired MMP. However, probucol could inhibit this rotenone-induced decrease in cell viability, MMP loss, intracellular ROS generation, and apoptosis. These results suggest that probucol exerts neuroprotective effects via MMP stabilization and the inhibition of ROS generation. Additionally, this effect of probucol was equal to or greater than and more persistent than that of edaravone. Thus, we believe probucol may be a promising drug for the treatment of neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases.
Asunto(s)
Apoptosis , Supervivencia Celular , Potencial de la Membrana Mitocondrial , Fármacos Neuroprotectores , Probucol , Especies Reactivas de Oxígeno , Rotenona , Probucol/farmacología , Rotenona/toxicidad , Humanos , Especies Reactivas de Oxígeno/metabolismo , Fármacos Neuroprotectores/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Apoptosis/efectos de los fármacos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Estrés Oxidativo/efectos de los fármacos , Antioxidantes/farmacologíaRESUMEN
A co-amorphous model drug was prepared by the spray-drying (SD) of probucol (PC) and atorvastatin calcium trihydrate salt (ATO) as low water solubility and co-former components, respectively. The physicochemical properties of the prepared samples were characterized by powder X-ray diffraction (PXRD) analysis, thermal analysis, Fourier transform infrared spectroscopy (FTIR), and dissolution tests. Stability tests were also conducted under a stress environment of 40 °C and 75% relative humidity. The results of PXRD measurements and thermal analysis suggested that PC and ATO form a co-amorphous system by SD. Thermal analysis also indicated an endothermic peak that followed an exotherm in amorphous PC and a physical mixture (PM) of amorphous PC and ATO; however, no endothermic peak was detected in the co-amorphous system. The dissolution profiles for PC in the co-amorphous sample composed of PC and ATO were improved compared to those for raw PC crystals or the PM. Stability tests indicated that the co-amorphous material formed by PC and ATO can be stored for 35 d without crystallization, whereas amorphous PC became crystallized within a day. Therefore, co-amorphization of PC and ATO prepared by SD is considered to be a useful method to improve the solubility of PC in water.
Asunto(s)
Probucol , Agua , Atorvastatina , Probucol/química , Estabilidad de Medicamentos , Cristalografía por Rayos X , Difracción de Rayos X , Agua/química , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Rastreo Diferencial de CalorimetríaRESUMEN
Cardiac remodeling has no established therapies targeting inflammation. CD4+ T-cell subsets have been reported to play significant roles in healing process after ischemic myocardial injury, but their detailed mechanisms of activation remain unknown. To explore immune reactions during cardiac remodeling, we applied a non-surgical model of coronary heart disease (CHD) induced by a high-fat diet (HFD-CHD) in SR-BI-/-/ApoeR61h/h mice. Flow cytometry analyses throughout the period of progressive cardiac dysfunction revealed that CD4+ T Helper 1 (Th1) cells were predominantly activated in T-cell subsets. Probucol was reported to attenuate cardiac dysfunction after coronary artery ligation model (ligation-MI) in rats. To determine whether probucol suppress cardiac remodeling after HFD-CHD, we treated SR-BI-/-/ApoeR61h/h mice with probucol. We found treatment with probucol in HFD-CHD mice reduced cardiac dysfunction, with attenuated activation of Th1 cells. RNA-seq analyses revealed that probucol suppressed the expression of CXCR3, a Th1-related chemokine receptor, in the heart. XCR1+ cDC1 cells, which highly expresses the CXCR3 ligands CXCL9 and CXCL10, were predominantly activated after HFD-CHD. XCR1+ cDC1 lineage skewing of pre-DC progenitors was observed in bone marrow, with subsequent systemic expansion of XCR1+ cDC1 cells after HFD-CHD. Activation of CXCR3+ Th1 cell and XCR1+ cDC1 cells was also observed in ligation-MI. Notably, post-MI depletion of XCR1+ cDC1 cells suppressed CXCR3+ Th1 cell activation and prevented cardiac dysfunction. In patient autopsy samples, CXCR3+ Th1 and XCR1+ cDC1 cells infiltrated the infarcted area. In this study, we identified a critical role of XCR1+ cDC1-activated CXCR3+ Th1 cells in ischemic cardiac remodeling.
Asunto(s)
Cardiopatías , Lesiones Cardíacas , Ratones , Ratas , Animales , Células TH1 , Probucol/metabolismo , Remodelación Ventricular , Cardiopatías/metabolismo , Células Dendríticas , Lesiones Cardíacas/metabolismoRESUMEN
BACKGROUND: Carotid artery stenosis is narrowing of the carotid arteries. Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease. It is caused by atherosclerosis; that is, the build-up of fats, cholesterol, and other substances in and on the artery walls. Atherosclerosis is more likely to occur in people with several risk factors, such as diabetes, hypertension, hyperlipidaemia, and smoking. As this damage can develop without symptoms, the first symptom can be a fatal or disabling stroke, known as ischaemic stroke. Carotid stenosis leading to ischaemic stroke is most common in men older than 70 years. Ischaemic stroke is a worldwide public health problem. OBJECTIVES: To assess the effects of pharmacological interventions for the treatment of asymptomatic carotid stenosis in preventing neurological impairment, ipsilateral major or disabling stroke, death, major bleeding, and other outcomes. SEARCH METHODS: We searched the Cochrane Stroke Group trials register, CENTRAL, MEDLINE, Embase, two other databases, and three trials registers from their inception to 9 August 2022. We also checked the reference lists of any relevant systematic reviews identified and contacted specialists in the field for additional references to trials. SELECTION CRITERIA: We included all randomised controlled trials (RCTs), irrespective of publication status and language, comparing a pharmacological intervention to placebo, no treatment, or another pharmacological intervention for asymptomatic carotid stenosis. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. Two review authors independently extracted the data and assessed the risk of bias of the trials. A third author resolved disagreements when necessary. We assessed the evidence certainty for key outcomes using GRADE. MAIN RESULTS: We included 34 RCTs with 11,571 participants. Data for meta-analysis were available from only 22 studies with 6887 participants. The mean follow-up period was 2.5 years. None of the 34 included studies assessed neurological impairment and quality of life. Antiplatelet agent (acetylsalicylic acid) versus placebo Acetylsalicylic acid (1 study, 372 participants) may result in little to no difference in ipsilateral major or disabling stroke (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.47 to 2.47), stroke-related mortality (RR 1.40, 95% CI 0.54 to 3.59), progression of carotid stenosis (RR 1.16, 95% CI 0.79 to 1.71), and adverse events (RR 0.81, 95% CI 0.41 to 1.59), compared to placebo (all low-certainty evidence). The effect of acetylsalicylic acid on major bleeding is very uncertain (RR 0.98, 95% CI 0.06 to 15.53; very low-certainty evidence). The study did not measure neurological impairment or quality of life. Antihypertensive agents (metoprolol and chlorthalidone) versus placebo The antihypertensive agent, metoprolol, may result in no difference in ipsilateral major or disabling stroke (RR 0.14, 95% CI 0.02 to1.16; 1 study, 793 participants) and stroke-related mortality (RR 0.57, 95% CI 0.17 to 1.94; 1 study, 793 participants) compared to placebo (both low-certainty evidence). However, chlorthalidone may slow the progression of carotid stenosis (RR 0.45, 95% CI 0.23 to 0.91; 1 study, 129 participants; low-certainty evidence) compared to placebo. Neither study measured neurological impairment, major bleeding, adverse events, or quality of life. Anticoagulant agent (warfarin) versus placebo The evidence is very uncertain about the effects of warfarin (1 study, 919 participants) on major bleeding (RR 1.19, 95% CI 0.97 to 1.46; very low-certainty evidence), but it may reduce adverse events (RR 0.89, 95% CI 0.81 to 0.99; low-certainty evidence) compared to placebo. The study did not measure neurological impairment, ipsilateral major or disabling stroke, stroke-related mortality, progression of carotid stenosis, or quality of life. Lipid-lowering agents (atorvastatin, fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin) versus placebo or no treatment Lipid-lowering agents may result in little to no difference in ipsilateral major or disabling stroke (atorvastatin, lovastatin, pravastatin, and rosuvastatin; RR 0.36, 95% CI 0.09 to 1.53; 5 studies, 2235 participants) stroke-related mortality (lovastatin and pravastatin; RR 0.25, 95% CI 0.03 to 2.29; 2 studies, 1366 participants), and adverse events (fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin; RR 0.76, 95% CI 0.53 to1.10; 7 studies, 3726 participants) compared to placebo or no treatment (all low-certainty evidence). The studies did not measure neurological impairment, major bleeding, progression of carotid stenosis, or quality of life. AUTHORS' CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.
Asunto(s)
Aterosclerosis , Estenosis Carotídea , Accidente Cerebrovascular Isquémico , Accidente Cerebrovascular , Humanos , Warfarina , Estenosis Carotídea/complicaciones , Estenosis Carotídea/tratamiento farmacológico , Metoprolol , Atorvastatina , Clortalidona , Fluvastatina , Pravastatina , Probucol , Rosuvastatina Cálcica , Accidente Cerebrovascular/prevención & control , Accidente Cerebrovascular/etiología , Hemorragia , Aspirina/efectos adversos , Accidente Cerebrovascular Isquémico/complicaciones , Aterosclerosis/complicacionesRESUMEN
Manganese (Mn) is an abundant element used for commercial purposes and is essential for the proper function of biological systems. Chronic exposure to high Mn concentrations causes Manganism, a Parkinson's-like neurological disorder. The pathophysiological mechanism of Manganism remains unknown; however, it involves mitochondrial dysfunction and oxidative stress. This study assessed the neuroprotective effect of probucol, a hypolipidemic agent with anti-inflammatory and antioxidant properties, on cell viability and oxidative stress in slices of the cerebral cortex and striatum from adult male Wistar rats. Brain structure slices were kept separately and incubated with manganese chloride (MnCl2) and probucol to evaluate the cell viability and oxidative parameters. Probucol prevented Mn toxicity in the cerebral cortex and striatum, as evidenced by the preservation of cell viability observed with probucol (10 and 30 µM) pre-treatment, as well as the prevention of mitochondrial complex I inhibition in the striatum (30 µM). These findings support the protective antioxidant action of probucol, attributed to its ability to prevent cell death and mitigate Mn-induced mitochondrial dysfunction.
Asunto(s)
Antioxidantes , Manganeso , Ratas , Animales , Masculino , Manganeso/toxicidad , Ratas Wistar , Antioxidantes/farmacología , Antioxidantes/metabolismo , Probucol/farmacología , Probucol/metabolismo , Neuroprotección , Estrés Oxidativo , EncéfaloRESUMEN
A reliable and efficient in vitro model is needed to screen drugs for Alzheimer's disease (AD), as many drugs are currently in the developmental stage. To address this, we developed an in vitro model using amniotic membrane-derived mesenchymal stem cells (AM-MSCs) to screen novel drugs for AD. We differentiated AM-MSCs into neurons and degenerated them using beta amyloid1-42 (Aß). We then tested AD drugs, which are commercially available such as donepezil, rivastigmine, memantine, citicoline, and two novel drugs, that is, probucol, an anti-hyperlipidaemic drug, and NMJ-2, a cinnamic acid analogue for their potential to protect the cells against neurodegeneration. We used gene expression and immunofluorescence staining to assess the neuroprotective ability of these drugs. We also measured the ability of these drugs to reduce lactate dehydrogenase, reactive oxygen species, and nitric oxide levels, as well as their ability to stabilize the mitochondrial membrane potential and increase acetylcholine (ACh) levels. The AD drugs and novel drugs reduced cytotoxicity and oxidative stress, stabilized mitochondrial membrane potential, and restored ACh levels. Furthermore, they reduced BACE1 expression, with a concomitant increase in the expression of cholinergic markers. This AM-MSCs-based AD-like model has immense potential to be an accurate human model and an alternative to animal models for testing a large number of lead compounds in a short time. Our results also suggest that the novel drugs probucol and NMJ-2 may protect against Aß-induced neurodegeneration.
Asunto(s)
Enfermedad de Alzheimer , Células Madre Mesenquimatosas , Animales , Humanos , Enfermedad de Alzheimer/metabolismo , Secretasas de la Proteína Precursora del Amiloide , Probucol/metabolismo , Evaluación Preclínica de Medicamentos , Ácido Aspártico Endopeptidasas , Células Madre Mesenquimatosas/metabolismoRESUMEN
PURPOSE: This study investigated the protective effect of probucol on Müller cells exposed to high glucose conditions and examined potential mechanisms of action. METHODS: Primary human retinal Müller cells were incubated with high glucose (HG, 35 mM) in the present or absence of different concentrations of probucol for 24 h. Cell viability was determined using the CCK-8 method. Mitochondrial membrane potential (MMP) was measured using JC-1 staining and cell cycle by flow cytometry. The expression of nuclear factor E2-related factor 2 (Nrf2), glutamate-cysteine ligase catalytic subunit, and p62 was quantified using quantitative polymerase chain reaction and western blot. RESULTS: We found that HG inhibited cell proliferation, arrested cell cycle, and increased MMP in human Müller cells. Probucol activated the Nrf2/p62 pathway and upregulated the anti-apoptotic protein, Bcl2, and attenuated HG-mediated damage in Müller cells. CONCLUSIONS: Our results suggest that probucol may protect Müller cells from HG-induced damage through enhancing the Nrf2/p62 signaling pathway.
Asunto(s)
Células Ependimogliales , Probucol , Transducción de Señal , Humanos , Células Ependimogliales/efectos de los fármacos , Células Ependimogliales/metabolismo , Glucosa/metabolismo , Glucosa/farmacología , Factor 2 Relacionado con NF-E2 , Probucol/farmacologíaRESUMEN
THE AIM OF THE STUDY: Was to evaluate the effectiveness and duration without a relapse period in patients with HPV-associated pathology of the oral mucosa and in combination with lesions of the anogenital region during combined therapy, including destruction and Panavir. MATERIALS AND METHODS: The study included 60 women diagnosed with «Viral warts. Genital condyloma of the oral cavity. 15 patients were also diagnosed with «Anogenital warts¼. The patients were divided into three groups of 20 women (15 with HPV-associated pathology of the oral cavity; 5 with combined HPV-associated pathology of the oral cavity and anogenital area). In the first group, the drug Panavir was administered intravenously. Between the third and fourth injections radiosurgical destruction of condylomas was carried out followed by Panavir gel applications until complete epithelialization of the destruction zone and further use of Panavir-inlight spray in the oral cavity and Panavir-intim spray in the anogenital area for 4 weeks. In the second group, the destruction of genital warts was carried out only with local treatment identical to that in the first group. In the third group after destruction applications of an oil solution of vitamin A were added to the oral mucosa 3-4 times a day until complete epithelization of the lesion, an alcohol solution of fucorcin and panthenol cream were applied externally in the anogenital area. RESULTS: According to clinical and laboratory monitoring after 3, 6 and 12 months, HPV elimination in the first group was achieved in 70, 85 and 90% of cases; in the second group in 50, 75 and 80%; in the third group in 30, 40 and 40%, respectively; within 12 months, relapses in the first group were registered in 10% of cases; in the second and third groups in 20% and 45% of cases, respectively. CONCLUSION: Combined therapy including destruction and complex use of different dosage forms of the drug Panavir showed higher clinical efficacy and allowed to achieve a reduction in the rate of condyloma relapses.
Asunto(s)
Infecciones por Papillomavirus , Radiocirugia , Verrugas , Humanos , Femenino , Mucosa Bucal , Infecciones por Papillomavirus/tratamiento farmacológico , ProbucolRESUMEN
Probucol (PBC) is a potent cholesterol-lowering drug and has been studied extensively for its powerful antioxidative stress. The purpose of this study is to investigate the role of PBC in ovariectomized rat model and to explore the mechanism of osteogenic differentiation of MC3TE-E1 Cells. RT-qPCR and Immunofluorescence were used to measure the expression level of SOD2, SIRT1, intracellular oxidative stress levels and osteogenic markers proteins. Moreover, CCK-8 assay was conducted to detect cell viability. Alizarin red staining and alkaline phosphatase staining were applied to examine osteogenic function and calcium deposits. The ovariectomized rat model was set up successfully and HE staining were employed to examine femoral trabeculae tissue. Our results showed that PBC suppressed MC3TE-E1 resist oxidative stress to promote osteogenic differentiation. Additionally, it was confirmed that PBC promoted osteogenic differentiation of MC3TE-E1 through inhibiting oxidative stress. Further study indicated that PBC exerted its beneficial function by suppressing oxidative stress-mediated alter bone metabolism to alleviate osteoporosis in vivo. Our research suggested that the PBC-modulated oxidative stress inhibition is responsible for activation of the process of osteogenic differentiation, providing a novel insight into the treatment of osteoporosis.
Asunto(s)
Osteogénesis , Osteoporosis , Animales , Osteoblastos , Osteoporosis/metabolismo , Osteoporosis/prevención & control , Estrés Oxidativo , Probucol/metabolismo , Probucol/farmacología , Probucol/uso terapéutico , RatasRESUMEN
The aim - to study and compare the sensitivity of museum strains of microorganisms to the herbal medicines. Standard strains of S. aureus ATCC 25923, S. epidermidis ATCC 14990, E. faecalis ATCC 29212, E. coli ATCC 25922 and C. albicans ATCC 10231 were used for the microbiological examination. Antimicrobial activity of the herbal medicines was studied by the disk diffusion method and serial dilutions method according to European Committee on Antimicrobial Susceptibility Testing. According to the obtained results E. coli standard strain is maximally sensitive to tymsal. Enterococci were statistically significant high sensitive to panavir only. Museum strain of S.epidermidis was 2.17 more sensitive to tymsal than to chlorhexidine control (p<0.05). Yeast like fungi standard strain was the most sensitive to proteflazid. Growth inhibition zone was showing the sensitiveness of C.albicans to this herbal medicine, the fungicidal activity was statistically significantly higher than chlorhexidine effect in 1.2 times (p<0.05). Analysis of microorganism's sensitivity to the herbal medicines action had showed the best antimicrobial activity of herbal medicines tymsal, panavir and proteflazid compared to traditional drugs.
Asunto(s)
Antiinfecciosos , Plantas Medicinales , Clorhexidina , Escherichia coli , Probucol , Staphylococcus aureus , Candida albicansRESUMEN
The elevated homocysteine level is an independent risk factor for atherosclerosis, which is characterized as a chronic inflammatory disease associated with oxidative stress. We have confirmed that homocysteine can stimulate the production of C-reactive protein (CRP) in rat aortic smooth muscle cells (RASMCs). In the present study, we investigated the role of probucol in homocysteine-induced CRP expression in cultured RASMCs and high-methionine-diet-induced hyperhomocysteinemic rats. The results showed that probucol decreased homocysteine-induced CRP mRNA and protein expression in RASMCs in a concentration-dependent manner. In addition, the animal experiment showed that probucol not only inhibited CRP expression in the vessel wall but also reduced the circulating CRP level in hyperhomocysteinemic rats. Further investigations revealed that probucol markedly increased heme oxygenase-1 activity, suppressed nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, diminished superoxide anion generation, and decreased p38 phosphorylation in RASMCs and hyperhomocysteinemic rat aorta. These data demonstrate that probucol can inhibit homocysteine-induced CRP generation by interfering with the NADPH oxidase/p38 signal pathway in RASMCs, which will provide new evidence for the anti-inflammatory and anti-atherosclerotic effects of probucol.
Asunto(s)
Aorta/metabolismo , Proteína C-Reactiva/biosíntesis , Hemo Oxigenasa (Desciclizante)/metabolismo , Homocisteína/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , NADPH Oxidasas/metabolismo , Probucol/farmacología , Especies Reactivas de Oxígeno/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , Animales , Ratas , Ratas Sprague-DawleyRESUMEN
This study was to explore the effect and mechanism of Probucol on STZ-induced erectile dysfunction in diabetic rats. Thirty SD male rats aged 12 weeks were given intraperitoneal injection of STZ after fasting for 12 hr. Diabetic rats were haphazardly partitioned under two assemblies and administered 0 or 500 mg/kg probucol by oral gavage to 12 weeks. Control group was intraperitoneally injected with physiological saline, and saline was administered by oral gavage daily. Intracorporeal pressure was used to evaluate erectile function. Levels of proteins were detected using immunohistochemistry and Western blotting. α-SMA and vWF were detected using immunofluorescence staining. After treatment, erectile function in probucol group was significantly improved. Endoplasmic reticulum stress-related proteins were expressed higher in DM group than in sham group, while expression of these proteins decreased significantly in probucol group. However, α-SMA and vWF were expressed at lower levels in DM group than in sham group, and probucol treatment reversed this phenomenon. Finally, Bax and Caspase3 were expressed at higher levels and Bcl-2 was expressed at lower levels in DM group, while the opposite result was obtained in probucol group. In conclusions, probucol improves erectile function by reducing endothelial dysfunction and inhibiting PERK/ATF4/CHOP pathway in STZ-induced diabetic rats.
Asunto(s)
Diabetes Mellitus Experimental , Disfunción Eréctil , Animales , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/tratamiento farmacológico , Estrés del Retículo Endoplásmico , Disfunción Eréctil/tratamiento farmacológico , Disfunción Eréctil/etiología , Humanos , Masculino , Probucol/farmacología , Probucol/uso terapéutico , Ratas , Ratas Sprague-Dawley , Estreptozocina/toxicidadRESUMEN
Atherosclerosis is a chronic inflammatory, metabolic, and epigenetic disease, which leads to the life-threatening coronary artery disease. Emerging studies from bench to bedside have demonstrated the pivotal role of low-density lipoprotein (LDL) oxidation in the initiation and progression of atherosclerosis. This article hereby reviews oxidation mechanism of LDL, and the pro-atherogenic and biomarker role of oxidized LDL in atherosclerosis. We also review the pharmacological effects of several representative natural products (vitamin E, resveratrol, quercetin, probucol, tanshinone IIA, epigallocatechin gallate, and Lycopene) in protecting against LDL oxidation and atherosclerosis. Clinical and basic research supports the beneficial effects of these natural products in inhibiting LDL oxidation and preventing atherosclerosis, but the data are still controversial. This may be related to factors such as the population and the dosage and time of taking natural products involved in different studies. Understanding the mechanism of LDL oxidation and effect of oxidized LDL help researchers to find novel therapies against atherosclerosis.
Asunto(s)
Antioxidantes/farmacología , Aterosclerosis/metabolismo , Suplementos Dietéticos , Lipoproteínas LDL/metabolismo , Extractos Vegetales/farmacología , Probucol/farmacología , Vitamina E/farmacología , Abietanos/farmacología , Abietanos/uso terapéutico , Antioxidantes/uso terapéutico , Aterosclerosis/tratamiento farmacológico , Productos Biológicos/farmacología , Productos Biológicos/uso terapéutico , Catequina/análogos & derivados , Catequina/farmacología , Catequina/uso terapéutico , Humanos , Licopeno/farmacología , Licopeno/uso terapéutico , Fitoterapia , Extractos Vegetales/uso terapéutico , Probucol/uso terapéutico , Quercetina/farmacología , Quercetina/uso terapéutico , Resveratrol/farmacología , Resveratrol/uso terapéutico , Vitamina E/uso terapéuticoRESUMEN
This study explored the effects of probucol on myocardial injury, oxidative stress, and Cav-3 and Smad3 expression in myocardial tissues by establishing VMC rat models, in order to provide a basis for exploring the mechanism of probucol in treatment of VMC. Sixty rats were randomly divided into control group, model group, probucollowdose group, andprobucol highdose group, with 15 in each group. Except for the control group, rats in each group were intraperitoneally injected coxsackievirus B3 diluent (0.2 ml) to replicate VMC models every 4 days. The results showed that Caspase-3 and Caspase-9, myocardial enzymes, cTn I, and MDA levels in the model group significantly increased (P < 0.05), while the SOD level significantly decreased (P < 0.05); and after probucol treatment, Caspase-3 and Caspase-9, myocardial enzymes, cTn I and MDA levels significantly decreased (P < 0.05), and the SOD level significantly increased (P < 0.05). Compared with the control group, there was an increase in myocardial fibers with significant lesions in the model group, and the pathological scores and the mRNA and protein expression levels of Cav-3 and Smad3 in myocardial cells significantly increased (P < 0.05). Compared with the control group, the myocardial tissue lesions were improved in the probucol low dose group and highdose group, and the pathological scores and the mRNA and protein expression levels of Cav-3 and Smad3 in myocardial cells were significantly reduced (P < 0.05). In conclusion, probucol can significantly improve the pathological damage of myocardial tissue in VMC rats, and its mechanism may be related to improving the expression of myocardium-related proteins Caspase-3 and Caspase-9, inhibiting oxidative stress response, and down-regulating Cav-3 and Smad3 gene expression in myocardial tissue of VMC rats.
Asunto(s)
Infecciones por Coxsackievirus , Miocarditis , Animales , Ratones , Ratones Endogámicos BALB C , Miocarditis/tratamiento farmacológico , Miocardio , Probucol/farmacología , RatasRESUMEN
In this study, the time-dependent evolution of amorphous probucol nanoparticles was characterized by cryogenic transmission electron microscopy (cryo-TEM) and atomic force microscopy (AFM). The nanoparticles were formed by dispersing ternary solid dispersions of probucol in water. Spray drying and cogrinding were used to prepare a spray-dried sample (SPD) and two ground-mixture samples (GM(I) and GM(II)) of probucol (PBC) form I and form II/hypromellose/sodium dodecyl sulfate ternary solid dispersions. The amorphization of PBC in the SPDs and GMs was confirmed using powder X-ray diffraction (PXRD) and solid-state 13C nuclear magnetic resonance (NMR) spectroscopy. Additionally, differential scanning calorimetry showed that relatively small amounts of PBC nuclei or PBC-rich domains remained in both GMs. Then, the physical stability of drug nanoparticles formed after aqueous dispersion in the SPD and GM suspensions during storage at 40 °C was characterized. Cryogenic transmission electron microscopy was used to monitor the evolution of the amorphous PBC nanoparticles in the SPD and GM suspensions during storage. Spherical nanoparticles smaller than 30 nm were observed in all of the suspensions just after dispersion. The size of the particles in the SPD suspension gradually increased but remained on the order of nanometers and retained their spherical shape during storage. In contrast, both GM suspensions evolved through three morphologies, spherical nanoparticles that gradually increased in size, needle-like nanocrystals, and micrometer-sized crystals with various shapes. The evolution of the nanoparticles suggested that their stability in the GM suspension was lower than in the SPD suspension. PXRD analysis of the freeze-dried suspensions of the particles showed that the PBC in the nanoparticles of the SPD suspension was in the amorphous state just after dispersion, while a small fraction of the PBC in the nanoparticles of the GM suspension exhibited a crystal phase and selectively crystallized to its initial crystal form during storage. AFM force-distance curves also demonstrated the existence of crystal phase PBC in the spherical nanoparticles in the GM suspension just after dispersion. The molecular state of PBC in the ternary solid dispersion was dependent on the preparation method (either completely amorphized or incompletely amorphized with residual nuclei or drug-rich domains) and determined the potential mechanisms of PBC nanoparticle evolution after aqueous dispersion. These findings confirm the importance of the molecular state on the particle evolution and the physical stability of the drug nanoparticles in the suspension. Cryo-TEM and AFM measurements provide more direct insight for designing solid dispersion formulations to produce stable amorphous drug nanosuspensions that efficiently improve the solubility and bioavailability of poorly water-soluble drugs.
Asunto(s)
Diseño de Fármacos , Microscopía de Fuerza Atómica/métodos , Microscopía Electrónica de Transmisión/métodos , Nanopartículas/química , Probucol/química , Agua/química , Disponibilidad Biológica , Rastreo Diferencial de Calorimetría , Cristalización , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Liofilización , Espectroscopía de Resonancia Magnética , Tamaño de la Partícula , Solubilidad , Suspensiones , Difracción de Rayos XRESUMEN
Pulmonary fibrosis is a progressive fibrotic lung disease with a paucity of therapeutic options. Here we investigated the potential roles of probucol, a cholesterol-lowering drug with potent anti-oxidation properties, on pulmonary epithelial-mesenchymal transition (EMT) and fibrosis. We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-ß1, α-smooth muscle actin (α-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation. Bleomycin treatment resulted in an induction of oxidative stress in lung tissues. Probucol treatment attenuated bleomycin-induced TGF-ß1 production, EMT and pulmonary fibrosis, meanwhile it suppressed bleomycin-induced oxidative stress. Bleomycin treatment resulted in decreases in protein expressions of Sirtuin 3 (SIRT3) in the lung, which were restored by ROS scavenger NAC and probucol treatment, suggesting that probucol might restore SIRT3 expression by suppressing bleomycin-induced oxidative stress. In the mouse alveolar type II epithelial cell line MLE-12, probucol treatment leads to an increase in SIRT3 expression in bleomycin-treated AT-II cells, which might contribute to the inhibitory effect of probucol on EMT through suppressing hypoxia inducible factor (HIF)-1α/TGF-ß1 pathway. In addition, probucol inhibited bleomycin-induced macrophage infiltration in the lung. Bleomycin decreased SIRT3 protein expression, whereas increased HIF-1α activation and TGF-ß1 release in the mouse macrophage cell line RAW264.7, which were attenuated by probucol treatment. Taken together, the present study suggests that probucol may ameliorate EMT and lung fibrosis through restoration of SIRT3 expression. The data obtained in this study provides proof for the idea that probucol may be a potential therapeutic option for the treatment of pulmonary fibrosis.
Asunto(s)
Transición Epitelial-Mesenquimal/efectos de los fármacos , Probucol/farmacología , Fibrosis Pulmonar/tratamiento farmacológico , Sirtuina 3/metabolismo , Actinas/metabolismo , Células Epiteliales Alveolares , Animales , Bleomicina/farmacología , Cadherinas/metabolismo , Técnicas de Cultivo de Célula , Colágeno Tipo I/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Ratones , Modelos Animales , Estrés Oxidativo/efectos de los fármacos , Fibrosis Pulmonar/inducido químicamente , Fibrosis Pulmonar/metabolismo , Fibrosis Pulmonar/patología , Células RAW 264.7 , Transducción de Señal/efectos de los fármacos , Sirtuina 3/biosíntesis , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
Probucol has antioxidant effects and inhibits inflammation. Farnesoid X receptor (FXR) is a nuclear receptor that regulates autophagy, which is regarded as the key cause of the activation of hepatic stellate cell (HSC). In this study, the effects of probucol on HSC activation and autophagy in vitro and vivo and the role of FXR in this progress were investigated. Results showed that probucol ameliorated hepatic fibrosis and autophagy, and increased the expression of FXR in liver in a mouse model of fibrosis induced by CCl4. And probucol could alleviate lipopolysaccharide-induced autophagy and HSC activation in vitro. In addition, probucol increased FXR expression, and the Z-guggulsterone, an antagonist of FXR, could block the effects of probucol on HSC activation and autophagy. Additionally, agonists of FXR could suppress LPS-induced autophagy and activation. These results suggest that probucol could ameliorate hepatic fibrosis, and inhibit HSC autophagy and activation, and these effects are associated with FXR.
Asunto(s)
Antioxidantes/farmacología , Células Estrelladas Hepáticas/efectos de los fármacos , Probucol/farmacología , Receptores Citoplasmáticos y Nucleares/metabolismo , Animales , Autofagia , Línea Celular , Células Cultivadas , Células Estrelladas Hepáticas/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/patología , Ratones Endogámicos C57BL , RatasRESUMEN
BACKGROUND: The results of pilot randomized controlled trials (RCTs) evaluating probucol treatment on the risk of contrast-induced acute kidney injury (CI-AKI) are inconsistent. We aimed to perform a meta-analysis of RCTs to systematically evaluate the influence of probucol on the incidence of CI-AKI. MATERIALS AND METHODS: Related RCTs were identified via searching of PubMed, Embase, and Cochrane's Library databases. Results were pooled using a random-effect model or a fixed-effect model according to the heterogeneity. RESULTS: Five RCTs with 1,367 patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) were included. Meta-analysis indicated that probucol in addition to periprocedural hydration significantly reduced the incidence of CI-AKI (risk ratio (RR): 0.37, 95% confidence interval (CI): 0.24 - 0.56, p < 0.001) with insignificant heterogeneity (I2 = 0%). Moreover, treatment with probucol significantly lowered the increment of serum creatinine (weighted mean difference (WMD): -0.04 mg/dL, 95% CI: -0.07 to -0.02 mg/dL, p < 0.001) and preserved the loss of estimated glomerular filtrating rate (WMD: 2.46 mL/min, 95% CI: 0.84 - 4.07 mL/min, p = 0.003) as compared with control treatment. No significant publication bias was noticed. CONCLUSION: Treatment with probucol reduces the incidence of CI-AKI in patients undergoing contrast exposure during CAG or PCI. The influence of probucol on the clinical outcome in these patients deserves further investigation.â©.